(Oslo, 20 July 2020)
Notice of exercise of employee share options
In connection with the expiry date at 31 March 2020, postponed by the Board of
Directors to no later than 30 September 2020, Kathrine Gamborg Andreassen, board
member, have at 20 July 2020 given notice that she will exercise a total of
125,000 options in Observe Medical ASA in the next exercise window.

Employees at Navamedic ASA were granted options in Observe Medical ASA in
connection with the demerger of Navamedic ASA's Medtech division with transfer
to Observe Medical ASA 31 October 2019. The weighted average option exercise
price is NOK 3.12. Shares issued upon exercise are subject to a lock-up period
of 24 months after exercise.
Mandatory notification of trade
Kathrine Gamborg Andreassen have at 20 July given notice that she will exercise
125,000 options in the Company, corresponding to 125,000 shares at the strike
price of NOK 3.12 in the next exercise window decided by the Board of Directors.

Kathrine Gamborg Andreassen, has today, at 20 July 2020, through her wholly
-owned company Soleglad Invest AS, sold 80,000 shares at an average price per
share of NOK 16.12.

Following these transactions, Kathrine Gamborg Andreassen (incl. Soleglad Invest
AS) will hold 586,668 shares and 0 options in the Company.

For further information, please contact:
Björn Larsson, CEO of Observe Medical
Mobile: +46 76 620 17 25
E-mail: bjorn.larsson@observemedical.com

About Observe Medical ASA:
Observe Medical develops and markets innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
Company's headquarter is in Oslo and its operations are based out of Sweden.
Observe Medical's initial product was Sippi®, the only digital urine meter with
wireless data transfer to patient data management systems, which also prevents
bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is
CE marked and is currently being launched at selected hospitals in the Nordics
and Germany.